ArticleLeukemia2021
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.
Abstract readLetter
In one paragraph
Article in Leukemia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort.Blood advances · 2026Article
- Review
- B Cell Subsets and Immune Checkpoint Expression in Patients with Chronic Lymphocytic Leukemia.Current issues in molecular biology · 2024Article
- Will New Drugs Replace Transplants for Chronic Lymphocytic Leukaemia?Journal of clinical medicine · 2021Review
- From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct.Cancers · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors.
Massimo GentileHematology Unit AO of Cosenza, Cosenza, Italy. massim.gentile@tiscali.it.ORCID http://orcid.org/0000-0002-5256-0726
Fortunato MorabitoBiothecnology Research Unit, AO of Cosenza, Cosenza, Italy.
Giovanni Del PoetaDivision of Hematology, S. Eugenio Hospital and University of Tor Vergata, Rome, Italy.
Francesca Romana MauroDivision of Hematology, Department of Translational and Precision Medicine, 'Sapienza' University, Rome, Italy.
Gianluigi RedaDivision of Ematologia, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.
Paolo SportolettiCentro di Ricerca Emato-Oncologica (CREO), University of Perugia, Perugia, Italy.ORCID http://orcid.org/0000-0002-5630-9862
Luca LaurentiFondazione Universitaria Policlinico A Gemelli di Roma, Roma, Italy.
Marta CosciaDivision of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy.
Yair HerishanuSourasky Medical Center, Institute of Hematology, and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Anna Grazia RecchiaBiothecnology Research Unit, AO of Cosenza, Cosenza, Italy.
Marzia VarettoniDivision of Haematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Roberta MurruHematology and Stem Cell Transplantation Unit, Ospedale A. Businco, Cagliari, Italy.
Annalisa ChiarenzaDivision of Hematology, Policlinico, Department of Surgery and Medical Specialties, University of Catania, Catania, Italy.
Adalgisa CondoluciDivision of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
Riccardo MoiaDivision of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
Daniela PietrasantaDivision of Hematology, Azienda Ospedaliera SS Arrigo e Biagio e Cesare Arrigo, Alessandria, Italy.
Giacomo LosetoHematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
Ugo ConsoliDepartment of Hematology, G. Garibaldi Hospital, Catania, Italy.
Ilaria ScortechiniClinica di Ematologia Ospedali Riuniti, Ancona, Italy.
Francesca Maria RossiClinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, (PN), Italy.
Antonella ZucchettoClinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, (PN), Italy.
Vincenzo FraticelliHematology Unit AO of Cosenza, Cosenza, Italy.
Ernesto VignaHematology Unit AO of Cosenza, Cosenza, Italy.
Cirino BottaHematology Unit AO of Cosenza, Cosenza, Italy.ORCID http://orcid.org/0000-0002-1522-4504
Giovanni TripepiCNR-IFC, Research Unit of Reggio Calabria, Reggio Calabria, Italy.
Graziella D' ArrigoCNR-IFC, Research Unit of Reggio Calabria, Reggio Calabria, Italy.
Angela RagoUOSD Ematologia ASL Roma 1, Roma, Italy.
Ilaria AngelettiReparto di Oncoematologia Azienda Ospedaliera Santa Maria di Terni, Terni, Italy.
Annalisa BiagiDivision of Hematology, S. Eugenio Hospital and University of Tor Vergata, Rome, Italy.
Ilaria Del GiudiceDivision of Hematology, Department of Translational and Precision Medicine, 'Sapienza' University, Rome, Italy.
Riccardo BombenClinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, (PN), Italy.
Gian Matteo RigolinHematology Section, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Davide RossiDivision of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
Francesco Di RaimondoDivision of Hematology, Policlinico, Department of Surgery and Medical Specialties, University of Catania, Catania, Italy.
Gianluca GaidanoDivision of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
Aaron PolliackDepartment of Hematology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Antonio CuneoHematology Section, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Robin FoàDivision of Hematology, Department of Translational and Precision Medicine, 'Sapienza' University, Rome, Italy.
Valter GatteiClinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, (PN), Italy. vgattei@cro.it.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdenineAntineoplastic Agents, ImmunologicalHumansLeukemia, Lymphocytic, Chronic, B-CellMolecular Targeted TherapyPiperidinesPrognosisProtein Kinase InhibitorsTreatment OutcomeAdenineAntineoplastic Agents, ImmunologicalibrutinibPiperidinesProtein Kinase Inhibitors
Identifiers
PMID
32286543What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.